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Autoimmune diseases comprise a heteroge-
neous group of poorly understood disorders 
that are controlled by genetic and environmen-
tal factors (1, 2). These diseases are most simply 
defi  ned by the presence of autoimmune phe-
nomena such as autoantibodies and/or autore-
active lymphocytes. Autoimmune diseases are 
generally classifi  ed into two major types: tissue 
specifi  c and systemic (2, 3). In tissue-specifi  c 
diseases, tissue-specifi   c autoantibodies or tis-
sue-specifi  c T lymphocytes play critical roles. 
However, there are some atypical autoimmune 
diseases that cannot be classifi  ed into either of 
these types. For example, an arthritis observed 
in TNF-α AU-rich element–deleted mice can 
be induced by a chronic infl  ammatory prolifer-
ative reaction that is dependent on TNF-α but 
not on adaptive autoimmunity; the TNF-α–
induced arthritis does not require mature lym-
phocytes, although these mice are positive for 
autoantibodies (4). Therefore, it is also possible 
that some cytokines, alone and in the absence 
of autoreactive lymphocytes, can induce tissue-
specifi  c autoimmune-like diseases (5, 6). In this 
regard, it is interesting that the epidermal-spe-
cifi   c deletion of junB and c-jun molecules, 
which enhances the expression of many cyto-
kines, induces psoriasis even in the absence of 
mature lymphocytes (7).
The immune system is well controlled to 
protect the host from exogenous pathogens. 
Because CD4+ T cells are critical for control-
ling the adaptive immune system, maintaining a 
certain level of antigen-specifi  c CD4+ T cells in 
a peripheral pool is important for the effi   cient 
elimination of exogenous pathogens (8). CD4+ 
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Mice homozygous for the F759 mutation in the gp130 interleukin (IL)-6 receptor subunit 
have enhanced gp130-mediated signal transducer and activator of transcription (STAT)3 
activation and spontaneously developed a lymphocyte-mediated rheumatoid arthritis-like 
joint disease. Here, we show that the development of the disease is dependent on both 
major histocompatibility complex (MHC) II–restricted CD4+ T cells and IL-6 family cyto-
kines. In spite of the necessity for CD4+ T cells, the gp130 mutation was only required in 
nonhemtopoietic cells for the disease. The gp130 mutation resulted in enhanced production 
of IL-7. Conditional knockout of STAT3 in nonlymphoid cells showed that the enhancement 
of IL-7 production was dependent on STAT3 activation by IL-6 family cytokines. Homeo-
static proliferation of CD4+ T cells was enhanced in gp130 mutant mice and acceleration 
of homeostatic proliferation enhanced the disease, whereas the inhibition of homeostatic 
proliferation suppressed the disease. Anti–IL-7 antibody treatment inhibited not only the 
enhanced homeostatic proliferation, but also the disease in gp130 mutant mice. Thus, our 
results show that autoimmune disease in gp130 mutant mice is caused by increased ho-
meostatic proliferation of CD4+ T cells, which is due to elevated production of IL-7 by 
nonhematopoietic cells as a result of IL-6 family cytokine-gp130-STAT3 signaling.
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T cells in peripheral organs are divided into two populations 
according to their expression of CD44 molecules: the 
  CD44high memory and CD44low naive phenotypes (9). It is 
hypothesized that the CD44low population consists of relative 
newcomers from thymus selection, whereas the CD44high 
memory cells are survivors in the peripheral environment. 
  Especially when the peripheral T cell number is low (i.e., in 
the neonatal condition, or after irradiation, chemotherapy, or 
viral infection), both CD4+ and CD8+ T cells proliferate 
  dramatically (10). This proliferation, termed “homeostatic 
proliferation” (HP), plays a critical role in maintaining the 
T cell number in the periphery (10). Homeostatic proliferat-
ing T cells show higher CD44 expression and cytokine secre-
tion and divide faster than CD44low naive cells (9). Because 
the CD44high memory phenotype T cells increase with age 
and divide slowly, even under normal, specifi  c pathogen-free 
(SPF) conditions, it is clear that HP is induced in normal 
healthy animals (9, 10). HP is strong in the neonatal period 
when thymus-derived naive T cells fi  rst migrate into the lym-
phopenic peripheral environment (11). Two known signals 
stimulate T cell HP. One is mediated by MHC–self-peptide 
complexes and the other is mediated by common γ cytokines, 
such as IL-7 and IL-15 (10, 12). In fact, CD4+ T cell HP is 
signifi  cantly impaired in MHCII- or IL-7–defi  cient mice 
(12, 13). Furthermore, the overexpression of IL-7 in vivo in-
duces autoimmune diseases, including dermatitis or colitis, in 
mice (14, 15). Recently, HP that produced IL-21 was shown 
to enhance autoimmune disease in NOD mice (16).
IL-6 is a pleiotropic cytokine that regulates multiple bi-
ological functions such as development of the nervous and 
  hematopoietic systems, acute-phase responses, infl  ammation, 
and immune responses (17). In rheumatoid arthritis (RA) pa-
tients, a high concentration of IL-6 is detected in the serum 
and joint fl   uids (18). Recently, important roles for proin-
fl  ammatory cytokines, such as TNF-α, IL-1, and IL-6 in the 
pathogenesis of RA have been reported (19, 20). The im-
portance of IL-6 has also been shown in SKG mice, a model 
of spontaneously occurring RA, and in antigen-induced RA 
models, such as CIA and AIA (21–23). Furthermore, treat-
ment with anti–IL-6 receptor is eff  ective for certain patients 
with RA (24).There are nine IL-6 family cytokines, includ-
ing IL-6, oncostatin M, LIF, CNTF, CT-1, IL-11, and IL-27 
(25). All the family members share gp130 as a receptor subunit 
and signal transducer (17). We previously showed that gp130 
transduces two major signaling pathways after stimulation with 
an IL-6 family cytokine. One is the JAK–STAT3 pathway, 
from its YxxQ motifs, and the other is the SHP2–Gab-Ras-
Erk–MAPK pathway, from the Y759 residue in its cytoplas-
mic portion (26). To investigate the in vivo function of these 
signaling pathways, we have established a series of knockin 
mice (27) and shown that one of these lines, gp130F759/F759 
(F759), spontaneously develops an RA-like disease in a man-
ner dependent on mature lymphocytes  1 yr after birth (28). 
The severity of the disease in the F759 is enhanced in an IL-
6–dependent manner by crossing the mice with p40-Tax Tg, 
human T cell leukemia virus 1 transgenic mice (29).
Here, we seek to clarify the immunological mechanisms 
by which the gp130F759/F759 mutation causes the RA-like 
  disease. Our results from F759 showed the involvement of 
enhanced CD4+ T cell HP caused by IL-6 family-gp130–
STAT3–IL-7 cascade in nonhematopoietic cells bearing the 
gp130F759/F759 mutation.
RESULTS
IL-6, MHCII-restricted CD4+ T cells and the gp130F759/F759 
mutation in nonhematopoietic cells are involved 
in the development of RA-like disease
We fi  rst examined whether development of RA-like disease 
in F759 was dependent on IL-6. We prepared a double mu-
tant, IL6KO/F759, and monitored its development of the 
disease. Both the severity and the incidence of the disease 
were signifi  cantly decreased in the IL-6–defi  cient F759 com-
pared with control F759 (Fig. 1 A), indicating the involve-
ment of IL-6 in disease development. However, the disease 
still developed in the absence of IL-6. Because the disease was 
dependent on the gp130F759/F759 mutation (28), these results 
suggested other IL-6 family cytokines are also involved in the 
disease in F759.
To identify the lymphocyte populations necessary for 
the disease, we generated the following four double mutant 
mice: Igh6KO/F759, CD4KO/F759, CD8KO/F759, and 
C2TAKO/F759. The Igh6KO/F759 showed almost the 
same progression of the disease as the control F759 (Fig. 1 B), 
but the CD4KO/F759 had signifi  cantly less severe arthritis 
(Fig. 1 B). However, CD8KO/F759 had signifi  cantly in-
creased score and incidence compared with the control mice 
(Fig. 1 B), showing that CD8+ T cells are dispensable, or 
rather suppressive for disease development. We hardly de-
tected the disease in C2TAKO/F759 (Fig. 1 B). Therefore, 
we concluded that MHCII-restricted CD4+ T cells were 
necessary but that CD8+ T or B cells were dispensable for 
the development of the arthritis in F759.
To investigate which tissues or cells needed to have the 
gp130 mutation for disease development, we divided all the 
cells in the body into two groups: hematopoietic and nonhe-
matopoietic. We performed BM transplantation using F759 
and wild-type congenic mice. Bone marrow cells derived 
from wild-type or F759 were transplanted into lethally irradi-
ated wild-type or F759. Chimerism, tested using BM cells, 
was >95% 8 mo after transplantation (unpublished data). We 
observed the disease developed in the two groups of chimeric 
mice in which nonhematopoietic cells had the gp130F759/F759 
mutation, regardless of the presence of the gp130F759/F759 mu-
tation in the hematopoietic cells 8 mo after BM transplanta-
tion; that is, the disease developed in the chimeric mice in 
which the host was F759 and the BM donor was either wild-
type or F759 (F759 having wild-type BM [62.5%, n = 8] and 
F759 having F759 BM [57.1%, n = 7]). Conversely, chime-
ric mice with a wild-type nonhematopoietic environment 
failed to develop the disease, regardless of the presence of the 
gp130F759/F759 mutation in the hematopoietic cells (wild-type 
host having wild-type BM [0%, n = 12] and wild-type host JEM VOL. 203, June 12, 2006  1461
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having F759 BM [0%, n = 10]). These results showed that 
the gp130F759/F759 mutation in nonhematopoietic cells was 
necessary for the development of the disease. Together, these 
results demonstrated that MHCII-restricted CD4+ T cells 
were critically involved, but that the gp130 mutation in the 
CD4+ T cells was not necessary for the disease. Therefore, 
we focused next on the roles played by CD4+ T cells and 
nonhematopoietic cell populations bearing the gp130F759/F759 
mutation in the development of the disease in F759.
Homeostatic proliferating CD4+ T cells are involved 
in the disease in F759
Because King et al. recently demonstrated that HP is involved 
in autoimmunity in NOD mice (16) and because we observed 
that F759 had more memory/activated phenotype CD4+ 
T cells than wild-type controls (Fig. 2 A) and that F759 had 
signifi  cant lymphoadenopathy and splenomegaly (28), we 
  hypothesized that enhanced HP of CD4+ T cells might be 
involved in the development of the disease in F759.
As expected, we found that the CD4+ T cell HP was 
enhanced in F759 compared with wild-type mice after ir-
radiation (Fig. 2 B). We next modifi  ed the speed of the HP. 
First, we used neonatal thymectomy to enhance HP; neonatal 
thymectomy suppresses T cells in the thymus from entering 
the peripheral environment, resulting in enhanced HP in the 
periphery (11). Here, we chose a day-7 thymectomy (NTx) 
to induce HP in vivo because Asano et al. demonstrated that 
NTx did not reduce CD25+CD4+ T (T reg) cells numbers 
and did not induce any autoimmune disease, whereas a day-3 
thymectomy (N3Tx) reduced the numbers of T reg cells and 
induced several autoimmune diseases (30). We confi  rmed 
that the CD4+ T cells in NTxed F759 divided more rap-
idly than those in NTxed wild-type controls or non-NTxed 
F759 (Fig. 2 C).
We also noted that the NTxed F759 had prominent 
lymphadenopathy and splenomegaly, suggesting an enhanced 
HP in F759 is a critical factor for determining the size of 
lymph nodes and spleen. The total cell number in the lymph 
nodes and spleen increased dramatically in F759 compared 
with wild-type mice after both were NTxed (Fig. 2, D and E). 
The numbers of CD4+ T cells in the lymph nodes and spleen 
increased signifi  cantly in the F759 compared with wild-type 
mice after NTx (Fig. 2 F). HP is reported to   induce memory/
activated phenotype CD4+ T cells (31). Consistent with this, 
the majority of the CD4+ T cells in NTxed wild-type and 
F759 showed the memory/activated phenotype (Fig. 2 G), 
suggesting that the enhanced CD4+ T HP in F759 acceler-
ated the accumulation of memory/  activated T cells.
Importantly, the NTxed F759 developed arthritis earlier 
than the sham-operated F759 (Fig. 3 A). We observed mono-
nuclear cell infi  ltration and hyperplasia of the synovial cells in 
F759 after NTx (unpublished data). In contrast, we observed 
few signs of disease in the wild-type mice, even after NTx 
(Fig. 3 A). We further confi   rmed that the disease in the 
NTxed F759, like that of the untreated F759, was dependent 
on MHCII-restricted CD4+ T cells (Fig. 3 B).
We next investigated whether the suppression of HP in 
F759 inhibits development of the disease. Because we showed 
a large number of CD4+CD25− T cells, fi  ller cells, suppressed 
Figure 1.  The arthritis of F759 is dependent on IL-6 and MHCII-
restricted CD4+ T cells. (A) Clinical score and incidence of arthritis in 
IL-6KO/F759 (closed circles, n = 10) and IL-6KO hetero/F759 or F759 (open 
circles, n = 10). (top) Data are the mean ± SEM of the arthritis scores. 
(bottom) Incidence of arthritis with a score >4.0. The p-value was calcu-
lated by Student’s t test. Clinical scores of 14–16-mo-old IL-6KO/F759 
were signifi  cantly lower than the control. (*, P < 0.05) (B) Clinical scores 
and incidences of arthritis in Igh6KO/F759 (open diamonds, n = 25), 
CD8KO/F759 (open squares, n = 30), CD4KO/F759 (closed triangles, n = 21), 
C2TAKO/F759 (open triangles, n = 19), and F759 (closed circles, n = 80). 
(top) Data are the mean ± SEM of the arthritis scores. (bottom) Incidence 
of arthritis with a score >2.0. Clinical scores of 6-12-mo-old CD8KO/F759 
were signifi  cantly higher (*, P < 0.05). Scores of 5–12-mo-old CD4KO/
F759 and C2TAKO/F759 were signifi  cantly lower. (*, P < 0.05).1462  IL-6–STAT3–IL-7 CAUSES AUTOIMMUNE DISEASE IN F759 MICE | Sawa et al.
Figure 2.  Increase in CD44highCD4+ T cells, lymphadenopathy, 
splenomegaly, and enhanced homeostatic proliferation in the periph-
ery of F759. (A) FACS profi  les of CD4+ T cells isolated from sLNs of F759 
and control mice (8–10 mo old). These experiments were performed three 
times independently; representative data are shown. The percentage of 
CD44highCD4+ T cells (CD62Lhigh and CD62Llow) is shown with error bars indi-
cating 1 SD. The p-value was calculated by Student’s t test (*, P = 0.0000025). 
(B) CD44lowCD4+ T cells were sorted from C57BL/6/SJL mice, labeled with 
CFSE, and injected into irradiated wild type or C57BL/6/F759. FACS pro-
fi  les of the CD45.1+CD4+T cells in the sLNs and spleen are shown. These 
experiments were performed fi  ve times independently and representative 
data are shown. The relative amount of CFSEhigh (most slowly dividing 
[A]), CFSEmiddle [B], and CFSElow (most rapidly dividing [C]) cells, with the 
value for CFSEhigh defi  ned as 1, is shown with error bars indicating 1 SD. 
The p-value was calculated by Student’s t test (*, P = 0.00037 and 
**, P = 0.000002). (C) CD44lowCD4+ T cells from C57BL/6/SJL were CFSE 
  labeled and injected into nonthymectomized and N7Txed C57BL/6 or 
C57BL/6/F759 neonates. FACS profi  les of CD45.1+CD4+ T cells from the 
sLNs and spleen are shown. These experiments were performed three 
times independently and representative data are shown. The relative JEM VOL. 203, June 12, 2006  1463
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HP (32), we transferred 3 × 107 or 3 × 106 fi  ller T cells to 
inhibit the HP of CD4+ T cells in the NTxed F759 neonates. 
As shown in Fig. 3 C, 3 × 107 fi  ller T cells almost completely 
suppressed the CD4+ T cell HP in NTxed F759. Moreover, 
we showed the injection of fi  ller T cells signifi  cantly sup-
pressed the disease (Fig. 3 D). Collectively, these results indi-
cated homeostatic proliferating CD4+ T cells were involved 
in the RA-like disease in F759.
It is well established that T reg cells play a role in various 
autoimmune disease developments (33). Moreover, a recent 
report suggested the important role of IL-6 secreted from 
DCs in the modulation of the T reg cell function (34). These 
reports suggested that a reduced T reg cell activity might 
cause the disease development in F759. However, this was 
not the case. We showed the following: (a) the percentages 
and numbers of CD25+GITR+CD4+ T cells were not al-
tered in F759 compared to control mice with or without 
N7Tx (Fig. S1, A and B, available at http://www.jem.org/
cgi/content/full/jem.20052187/DC1, and not depicted); (b) 
FoxP3 expressions in CD25+CD4+ T cells did not decrease 
in F759 with or without N7Tx compared with these from 
control mice (Fig. S1 C); and (c) suppressive activity for pro-
liferation of CD25−CD4+ T cells in vitro is not altered be-
tween T reg cells isolated from F759 with or without N7Tx 
and T reg cells from control mice (Fig. S1 D). With the data 
that (a) fi  ller CD4+CD25− T cells (Fig. 3 D), (b) the report 
by Asano et al. that T reg cell activity disappeared by N3Tx 
but not N7Tx (30), (c) we did not see any diff  erences for the 
disease development between F759 N3Txed and N7Txed 
(Fig. S1 E), and (d) injection of anti–IL-2 Abs during neona-
tal period (which effi   ciently eliminates T reg cells in vivo 
[references 32, 35]) did not accelerate the disease in F759 
(not depicted), we concluded that T reg cells have a mini-
mum role in RA-like disease in F759 model.
The IL-6/IL-6 family-gp130–STAT3–IL-7 cascade exists 
in nonhematopoietic cells
We next asked whether the gp130F759/F759 mutation in the 
nonhematopoietic cell population plays a role in the en-
hanced HP of CD4+ T cells in the F759. To investigate this 
possibility, we fi  rst focused on IL-7 and TSLP because these 
cytokines are reported to enhance CD4+ T cell HP (12, 36). 
We showed that the amount of mRNA per cell for IL-7, but 
not for TSLP, signifi  cantly increased in the lymphoid organs 
of the F759 compared with the controls (Fig. 4 A and not 
depicted) as well as after sublethal irradiation and NTx (Fig. 
4, B and C), suggesting the gp130F759/F759 mutation in non-
hematopoietic cells aff  ected the IL-7 expression in vivo. The 
IL-7 expression was correlated with IL-6 expression in the 
F759 (Fig. 4, C–E), suggesting the existence of a cascade for 
IL-6–mediated IL-7 expression.
Because the major IL-7–producing populations are re-
ported to be nonhematopoietic cells (37), we investigated 
whether the IL-7–producing cells in NTxed F759 are also 
nonhematopoietic cells. As expected, the major IL-7–
  expressing cell populations in the F759 were nonhemato-
poietic cells (Fig. 4 F). These results suggested that IL-6 or 
IL-6 family cytokines acting on nonhematopoietic cells with 
the gp130F759/F759 mutation resulted in the enhanced expres-
sion of IL-7 in nonhematopoietic cells. Consistent with this, 
IL-7 mRNA expression in the surface LNs (sLNs) (with and 
without irradiation) was enhanced by IL-6 in vivo (Fig. 5, A 
and B). Moreover, to know whether IL-6 directly induces 
IL-7 production in nonhematopoietic cells, we stimulated 
primary fi  broblasts isolated from F759 and control mice with 
IL-6. As shown in Fig. 5 C, IL-6 signifi  cantly enhanced the 
expression of IL-7 mRNA in F759 fi  broblasts  compared 
with the vehicle controls. IL-6 stimulation showed little ef-
fect on IL-7 expression in control fi  broblasts (Fig. 5 C), but it 
signifi  cantly induced IL-7 in the presence of soluble receptor 
of IL-6 (Fig. 5 D).
It is known that IL-6 family cytokines such as IL-
11, CT-1, OSM, and LIF share gp130 as a signal trans-
ducer (25). Moreover, because we showed that IL-6 just 
partially plays a role in the disease development in F759 
(Fig. 1 A), other IL-6 family cytokines were suggested to 
be involved in disease development. Therefore, we hy-
pothesized that not only IL-6 but also other IL-6 family 
members induced IL-7, which is a critical factor for dis-
ease development. In fact, sIL-6R plus IL-6, OSM, LIF, 
IL-11, or CT-1 induced IL-7 mRNA in primary fi  broblasts 
(Fig. 5 E and not depicted). We hypothesized that gp130-
STAT3 signaling, but not gp130-SHP2/MAPK, plays an 
important role for IL-7 expression because F759 fi  broblasts, 
which are defective of the gp130-SHP2/MAPK pathway 
but show an enhanced gp130–STAT3 pathway as the result 
of Y759F mutation, expressed more IL-7 after IL-6 treat-
ment compared with control (Fig. 5 C). Consistent with 
this, IL-6 plus sIL-6R stimulation failed to induce IL-7 
mRNA in mouse embryonic fi  broblasts (MEFs) prepared 
amount of CFSEhigh (A), CFSEmiddle (B), and CFSElow (C) cells, with the value 
for CFSEhigh defi  ned as 1, is shown with error bars indicating 1 SD. The 
p-value was calculated by Student’s t test (*, P = 0.0017 and **, P = 0.0008). 
(D and E) The sLNs (D) and spleen (E) were from and the total cell numbers 
were calculated. The mean is shown with error bars indicating 1 SD. The 
p-value was calculated by Student’s t test (*, P = 0.0042; **, P = 0.0038; 
***, P = 0.00034; and ****, P = 0.00027). (F) The sLNs and spleen were 
harvested from NT7xed C57BL/6 and C56BL/6/F759. The numbers of CD4+ 
T cells were calculated from FACS analyses (open circles; N7Txed F759 and 
open triangles; N7Txed wild type). The mean is shown as open (N7Txed 
wild type) and closed (N7Txed F759) bars. The p-value was calculated by 
Student’s t test (*, P = 0.0065; **, P = 0.0068; ***, P = 0.00034; and ****, 
P = 0.00021). (G) Neonatal thymectomy increased the CD44high memory/
activated CD4+ T cells in the spleen of NTx F759. FACS profi  les of CD4+ 
T cells isolated from the spleen of N7Txed or sham-N7Txed F759 and wild-
type mice (2 wk old). These experiments were performed twice indepen-
dently (total 12 samples each) and representative data are shown. The 
percentage of CD44highCD4+ T cells (CD62Lhigh and CD62Llow) is shown with 
error bars indicating 1 SD. The p-value was calculated by Student’s t test 
(*, P = 0.024; **, P = 0.0032; ***, P = 0.00000039; and ****, P = 0.0000002).1464  IL-6–STAT3–IL-7 CAUSES AUTOIMMUNE DISEASE IN F759 MICE | Sawa et al.
from   gp130FxxQ/FxxQ knockin (FxxQ) mice, which are de-
fective in gp130-meditaed STAT3 activation (27) (Fig. 5 F, 
top left, and not depicted). Additionally, we showed that 
IL-7 protein increased in MEF from F759 compared with 
wild-type controls after stimulation of IL-6 plus sIL-6R 
(Fig. 5 G). We performed a critical experiment using type 
I–  collagen–Cre/STAT3fl  ox/fl  ox mice (Col1a-STAT3). IL-6 
plus sIL-6R stimulation did not induce IL-7 expression in 
vitro in lymph nodes of Col1a-STAT3 (Fig. 5 F, top right). 
Moreover, in vivo expression of IL-7 in lymph nodes of 
irradiated Col1a-STAT3 was sig  nifi  cantly lower compared 
with controls (Fig. 5 F, bottom).   Furthermore, we showed 
there is almost no IL-7 protein expression in lymph nodes 
of Col1a-STAT3 after irradiation (Fig. 5 H). Together with 
the existence of a STAT3 binding site in the IL-7 promoter 
region (unpublished data), these results indicated that the 
IL-6/IL-6 family-gp130-STAT3-IL-7 cascade existed in 
the nonhematopoietic cells.
Figure 3.  CD4+ T cell homeostatic proliferation played a critical 
role for the disease development in F759. (A) Clinical score and inci-
dence of arthritis in N7Txed F759 (open circles, n = 30), F759 hetero or 
N7Txed wild-type (open triangles, n = 24), and sham-Txed F759 (closed 
circles, n = 20). (top) Data are the means ± SEM of the arthritis scores. 
(bottom) Incidence of arthritis with a score >2.0. Clinical scores of 
10–30-wk-old N7TxF759 were signifi  cantly higher than the sham N7Tx 
ones (*, P < 0.05). (B) Data are the means ± SEM of the arthritis score in 
N7Txed F759 (open circles, n = 12), N7Txed CD4KO/F759 (closed triangles, 
n = 12), and N7Txed C2TAKO/F759 (open triangles, n = 12). Clinical 
scores of N7Txed CD4KO/F759 and N7Txed C2TAKO/F759 (13–30 wk old) 
were significantly milder than N7Txed F759 ones (*, P < 0.05). 
(C) CD44lowCD4+ T cells from C57BL/6/SJL were labeled with CFSE and 
injected i.v. with or without fi  ller T cells injected i.p. into N7Txed C57BL/6/
F759 neonates. FACS profi  les of CD45.1+CD4+ T cells from sLNs and 
spleen are shown. These experiments were performed three times inde-
pendently and representative data are shown. The relative amount of 
CFSEhigh (A), CFSEmiddle (B), and CFSElow (C) cells, with the value for CFSEhigh 
defi  ned as 1, is shown with error bars indicating 1 SD. (D) Incidence of 
arthritis with a score >2.0 in N7Txed F759 plus saline (open circles, n = 14), 
N7Txed F759 plus i.p. injection of fi  ller T cells (closed triangles, n = 14) 
and sham-N7Txed F759 (closed circles, n = 15).JEM VOL. 203, June 12, 2006  1465
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IL-7 expression is involved in enhanced CD4+ T cell HP 
and is necessary for the development of the disease 
in F759 neonates
We next asked whether the enhanced CD4+ T cell HP in 
F759 is dependent on an enhanced production of IL-7. We 
transferred CFSE-labeled CD4+ T cells into F759 neonates 
1 d after NTx and injected an anti–IL-7 antibody. The in vivo 
depletion of IL-7 by the antibody treatment strongly sup-
pressed CD4+ T cell HP in the F759 neonates, whereas the 
IL-7 depletion in wild-type controls showed a minimal eff  ect 
on CD4+ T cell HP, as demonstrated by Min et al. (reference 
11 and Fig. 6 A), showed an enhanced IL-7 production via 
gp130 signaling was involved in the enhanced HP of CD4+ 
T cells in F759 neonates.
Finally, we analyzed the contribution of IL-7 on the de-
velopment of the disease in NTxed F759. We showed that the 
anti–IL-7 antibody that signifi  cantly inhibited the gp130F759/F759-
mediated enhancement of CD4+ T cell HP almost com-
pletely suppressed the disease in NTxed F759, whereas con-
trol IgG2b had no eff  ect on the disease development (Fig. 6 B 
and not depicted). We could not suppress the disease devel-
opment after injection of anti–IL-7 antibody in the neonatal 
period of F759 without a thymectomy (unpublished data). 
This ineff  ectiveness of the antibody treatment might be a re-
sult of the diffi   culty to maintain enough amount of anti–IL-7 
antibody in vivo during a long period, such as 1 yr. However, 
we showed that IL-7RKO/F759 did not develop the disease 
in age (the disease incidence was 11% in IL-7RKO/F759 and 
84% in control F759 mice at 12 mo old [n = 8 and n = 12, 
respectively]). From all the aforementioned results, we con-
cluded that, in the F759, the overexpression of IL-7 mediated 
through the IL-6/IL-6 family-gp130–STAT3 signaling in 
nonhematopoietic cell populations was involved in both the 
accelerated HP of CD4+ T cells and disease development.
D  I  S  C  U  S  S  I  O  N 
We demonstrated previously that Rag2KO background F759 
did not develop the disease (28), clearly indicating that ma-
ture lymphocytes, CD4+ T cells, CD8+ T cells, and B cells 
are responsible for disease development. Here, we neglected 
the possible involvement of CD8+ T cells and B cells for the 
enhancement of the disease. CD8+ T cells are suppressive, 
although the mechanism of this phenomenon of CD8+ 
T cells should be clarifi  ed by additional studies after confi  rm-
ing it. From these results, it is reasonable to conclude that 
CD4+ T cells play a role in the disease of F759. In fact, we 
showed signifi  cant reduction of the disease severity in CD4-
defi  cient F759 compared with control F759, indicating that, 
at least in part, CD4+ T cells are involved in the disease. We 
should note that CD4-defi  cient mice contain T cells able to 
recognize MHCII molecules (38). This may explain why the 
  disease developed without CD4+ cells.
We observed that CIITAKOF759 clearly prevented 
induction of the disease, whereas CD4-defi  cient F759 ani-
mals show less protection from the disease. We hypothesize 
three possibilities to explain this phenomenon. First, as we 
described in previous paragraphs, CD4-defi  cient mice con-
tain many T cells able to recognize MHCII molecules (38), 
whereas there is a limited number of MHCII-restricted CD4+ 
T cells in CIITAKO mice. Second, it is known that CIITA 
can infl  uence transcription of MHCII plus multiple accessory 
genes for MHCII antigen presentation including H2DM, Ii, 
Plexin A1, and cathepsin E (39–41). Because   accessory mole-
cules are not able to work for CD4+ T cell responses without 
MHCII molecules, a reasonable primary defect of CIITA is 
MHCII defi  ciency in antigen-presenting cells. However, it 
was also reported that CIITA induces MMP9 and collagen 
(COL1A2) transcriptions (42, 43). In the case of these two 
genes, their expression levels in synovial cells derived from 
F759 were not changed compared with wild-type controls 
Figure 4.  Increased IL-7 expression in nonhematopoietic cells in 
F759. (A) The sLNs were harvested from wild-type C57BL/6 and C57BL/6/
F759. Real-time PCR for IL-7 was performed. (B) The sLNs were harvested 
from wild-type C57BL/6 and C57BL/6/F759 10 d after irradiation. Real-time 
PCR was performed for IL-7. (C and D) The sLNs were harvested from 
N7Txed wild-type C57BL/6 and C57BL/6/F759 10 d after N7Tx. Real-time 
PCR was performed for IL-7 (C) and IL-6 (D). The mean is shown with error 
bars indicating 1 SD. The p-value was calculated by Student’s t test (*, P = 
0.0021; **, P = 0.011; ***, P = 0.00041; and ****, P = 0.000000003). These 
experiments were performed three times independently and representa-
tive data are shown. (E) The correlation between relative IL-7 and IL-6 
expression in N7Txed wild-type or F759 is shown. The correlation effi  -
ciency was 0.88. (F) The sLNs were harvested from C57BL/6/F759. The cell 
strainer pass-through and the retained fractions were prepared. Real-time 
PCR was performed for IL-7. The mean is shown with error bars indicating 
1 SD. The p-value was calculated by Student’s t test (*, P = 0.0021). These 
experiments were performed three times independently and representa-
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Figure 5.  IL-6 injection induced IL-7 in vivo and gp130-STAT3 
directly induced IL-7 in the fi  broblasts of F759. (A) IL-6KO/F759 
(nonirradiated) with i.v. injection IL-6 was prepared. Real-time PCR for IL-7 
or SOCS3 was performed using RNA from the sLNs of the IL-6KO/F759. 
These experiments were performed two times independently and the sum 
of the data is shown. (B) IL-6 KO mice with irradiation 24 h before the i.v. 
injection of IL-6 was prepared. Real-time PCR for IL-7 was performed 
using RNA from the sLNs. These experiments were performed three times 
independently and representative data are shown. The p-value was calcu-
lated by Student’s t test (in A: *, P = 0.034; **, P = 0.018). In B, *, P = 0.016. 
(C) Splenic fi  broblasts were prepared and stimulated with IL-6. Real-time 
PCR was performed for IL-7 and SOCS3. The mean is shown with error 
bars indicating 1 SD. Student’s t test was done between IL-6–treated and 
untreated cells. The p-value was calculated by Student’s t test (*, P < 0.05 
and **, P < 0.01). These experiments were performed three times inde-
pendently and representative data are shown. (D) Splenic fi  broblasts pre-
pared from wild-type neonates were stimulated with IL-6 plus sIL-6R. 
Real-time PCR was performed for IL-7 and SOCS3. The mean is shown 
with error bars indicating 1 SD. The p-value was calculated by Student’s 
t test (*, P = 0.010 and **, P = 0.014). These experiments were performed 
three times independently and representative data are shown. (E) Splenic 
fi  broblasts from F759 were stimulated with IL-6 plus sIL-6R, OSM, and LIF. 
Real-time PCR was performed for IL-7 and SOCS3. The mean is shown 
with error bars indicating 1 SD. The p-value was calculated by Student’s 
t test (*, P < 0.05 and **, P < 0.01). These experiments were performed 
three times independently and representative data are shown. (F, top 
left) MEF were prepared from FxxQ or wild-type fetus were stimulated 
with IL-6 plus sIL-6R. Real-time PCR was performed for IL-7. The mean 
is shown with error bars indicating 1 SD. The p-value was calculated by 
Student’s t test (**, P < 0.01). These experiments were performed three 
times independently and representative data are shown. (top right) 
Col1a-STAT3, control (STAT3fl  ox/fl  ox or type I-collagen-Cre/STAT3fl  ox/+), and 
F759 were irradiated, and the sLNs were harvested and cultured with 
IL-6 plus sIL-6R. Real-time PCR for IL-7 was performed using sLNs. The 
mean is shown with error bars indicating 1 SD. The p-value was calcu-
lated by Student’s t test (*, P < 0.05). These experiments were performed 
three times independently and representative data are shown. (bottom) 
Col1a-STAT3, control, and F759 were irradiated. Real-time PCR for IL-7 
or SOCS3 was performed using the lymph nodes. The mean is shown 
with error bars indicating 1 SD. The p-value was calculated by Student’s 
t test (*, P < 0.05; **, P < 0.01). These experiments were performed 
three times independently and representative data are shown. (G) MEF 
were prepared from F759 or wild-type fetus were stimulated with IL-6 
plus sIL-6R. Their protein fractions were prepared and applied on SDS-
page followed by Western blotting of IL-7. (H) The sLNs irradiated 
Col1a-STAT3, wild-type, and F759 were harvested. Their protein frac-
tions were prepared and applied on SDS-page followed by Western 
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(unpublished data). Third, enhanced HP of T cells acceler-
ates the disease, whereas either fi  lling the fi  ller CD4+ T cells 
or anti–IL-7 treatment, which prevents the HP of CD4+ T 
cells, suppressed the disease. These results further support the 
involvement of CD4+ T cells in the disease, although we 
cannot completely neglect the possible involvement of un-
known genes controlled by CIITA.
We showed that the enhanced CD4+ T cell HP that is 
induced by gp130–STAT3-mediated IL-7 expression in 
nonhematopoietic cells is critical for the development of the 
disease in F759. Signifi  cant HP occurs at the beginning of life 
in neonates, but HP lasts in adults even under SPF conditions 
(10, 11). We showed that CD4+ T cell HP was enhanced in 
both the neonates and adults of F759 compared with wild-
type controls. Importantly, we showed that the enhanced HP 
in the F759 was involved in the development of the disease. 
There are three observations that directly support this con-
clusion. First, thymectomy in the neonatal period enhanced 
both the CD4+ T cell HP and the development of the   disease. 
Second, either the transfer of fi  ller CD4+ T cells or, third, the 
depletion of IL-7 inhibited the CD4+ T cell HP and sup-
pressed the disease.
How is the HP of CD4+ T cells enhanced in F759? The 
rate of HP is known to be dependent on both TCR-MHC 
and cytokine signaling (12, 13, 44). We identifi  ed IL-7 from 
nonhematopoietic cell populations as a key cytokine for en-
hancing the HP of CD4+ T cells in F759. Because it was an 
unexpected fi  nding that gp130 signaling induced IL-7, we 
performed eight independent experiments to show the exis-
tence of this pathway. First, it is reported that the main source 
of IL-7 is nonhematopoietic cells (37), and we confi  rmed a 
connective tissue-enriched fraction, which mainly consisted 
of nonhematopoietic cells, expressed IL-7 in F759. Second, 
we showed the IL-7 mRNA and protein expression increased 
in F759, especially after induction of HP. Third, conversely, 
IL-7 mRNA and protein expression was signifi  cantly de-
creased in Col1a-STAT3. Fourth, we confi  rmed both splenic 
fi  broblasts and MEF expressed IL-7 after stimulation of gp130 
signaling. Fifth, STAT3 binding sites of gp130 were critical 
for IL-7 mRNA expression in MEFs after IL-6 plus sIL-6R 
stimulation. Sixth, IL-6 injection induced IL-7 expression in 
lymph nodes in vivo. Seventh, we showed IL-7 protein in-
creased in MEFs from F759 compared with these from wild-
type controls after stimulation of IL-6 plus sIL-6R. Eighth, 
IL-7 depletion suppressed the HP of CD4+ T cells in F759. 
Thus, we concluded that a gp130–STAT3–IL-7 cascade in 
nonhematopoietic cells is critical for the enhancement of 
CD4+ T cell HP in F759.
Because we showed that the disease development was at 
least in part dependent on IL-6, consistent with our previous 
observation that the human T cell leukemia virus 1 p40Tax-
induced enhancement of the disease in F759 is dependent on 
IL-6 (29), we suggest that IL-6 is at least partly involved in the 
gp130-mediated IL-7 expression in vivo. There are nine IL-6 
family members reported, which include IL-6, IL-11, IL-27, 
oncostatin M, LIF, and CNTF (25). Because all of their re-
ceptors share gp130 as a subunit, it is likely that other IL-6 
family cytokines also play a role in the gp130–STAT3–IL-7 
cascade. Therefore, we hypothesized that the reason why we 
had signifi  cant numbers of animals that developed the disease 
even in the absence of IL-6 is that other IL-6 family members 
function as IL-7 inducers in IL-6KO/F759. Consistent with 
this hypothesis, we showed that other IL-6 family members 
induced a signifi  cant level of IL-7 in primary fi  broblasts. We 
also showed HP increased IL-6 expression in vivo in the 
F759. Interestingly, we also showed IL-7 expression was cor-
related with IL-6 expression in the F759 thymectomized.
How does the enhancement of CD4+ T cell HP induce 
the disease in F759? We have not detected a bias of the T 
cell receptor repertoire toward CD4+ T cells in F759 with 
the disease (unpublished data), although the memory/ac-
tivated CD4+ T cells were increased in F759. At present, 
Figure 6.  IL-7 expression was involved in the enhanced CD4+ 
T cell HP and was necessary for development of the disease in F759 
neonates. (A) CD44lowCD4+ T cells were sorted from C57BL/6/SJL mice, 
labeled with CFSE, and injected into N7Txed C57BL/6 or C57BL/6/F759 
neonates 8 d after birth. Anti–IL-7 antibody (dotted lines) or control 
IgG2b antibody (shaded profi  les, 0.1 mg/each) was i.p. injected. The sLNs 
and spleen were harvested 14 d after T cell injection and FACS profi  les of 
CD45.1+CD4+ T cells are shown. These experiments were performed three 
times independently and representative data are shown. The relative 
amount of CFSEhigh (A), CFSEmiddle (B), and CFSElow (C) cells, with the value 
for CFSEhigh defi  ned as 1, is shown with error bars indicating 1 SD. The 
p-value was calculated by Student’s t test (*; P = 0.012; **, P = 0.00023). 
(B) Incidence of arthritis with a score >2.0 in N7Txed F759 plus saline 
(open circles) or N7Txed F759 plus anti–IL-7 antibody (closed circles).1468  IL-6–STAT3–IL-7 CAUSES AUTOIMMUNE DISEASE IN F759 MICE | Sawa et al.
we cannot completely exclude the possibility that a minor 
population of antigen-specifi  c CD4+ T cells among the ho-
meostatic proliferating T cells plays a pathogenic role, but 
our data strongly support the idea that nonspecifi  c antigen-
proliferating CD4+ T cells play a central role in causing the 
tissue-specifi  c RA-like disease via HP in a manner dependent 
on the gp130F759/F759 mutation of nonhematopoietic cells. In 
this regard, it is also interesting that B cells are not required 
for the disease in F759, although abundant autoantibodies 
are produced in these mice (28). This fi  nding suggests that 
the apparent adaptive autoimmunity, such as autoantibody 
production, observed in the F759, is merely a consequence 
of the infl  ammatory response of the disease. We hypothesize 
that the HP-mediated activation of CD4+ T cells in F759 
is a critical inducer or source of cytokines for the induction 
of the disease because the HP of CD4+ T cells is a type of 
CD4+ T cell activation in vivo and induces the expression of 
many cytokines from themselves and from DCs (45, 46).
As for the role of the IL-6 family cytokines, we propose 
two possibilities. One is that IL-6 family cytokines act only as 
a stimulator of CD4+ T cell HP through IL-7 production, 
but not as an eff  ector molecule for disease induction. In this 
case, it may be possible that some cytokines other than IL-6 
family cytokines that are induced by the enhanced HP of 
CD4+ T cells function as eff  ectors for the disease develop-
ment. The second scenario is that IL-6 family cytokines act 
not only as a stimulator of the HP of CD4+ T cells but also as 
a direct eff  ector molecule for disease induction. If the second 
scenario is fi  t to this F759 model, IL-6/IL-6 family–mediated 
gp130F759/F759 signaling in nonhematopoietic tissues, most 
likely in the joint, could play a major role in the development 
of the disease. Because IL-6 is known to be a survival factor 
for synovial fi  broblastic cells in the presence of soluble IL-6 
receptor (47) and activated CD4+ T cells express IL-6 family 
cytokines (unpublished data), it is likely that a hyperactivated 
STAT3 status caused by gp130F759/F759 signaling is involved in 
the bone destruction or overproliferation of synovial fi  bro-
blastic cells in the F759. Such aberrant gp130F759/F759 signaling 
directly or indirectly induced in joints via the enhanced HP 
of CD4+ T cells in F759 could cause tissue-specifi  c diseases.
Nevertheless, we emphasize that MHCII-restricted CD4+ 
T cells were required for the disease in the F759. This may 
indicate that we should consider the environmental factors 
that cooperate with genetic factors to promote autoimmune 
diseases in patients. We hypothesize that certain environmen-
tal factors, including infectious agents, may induce the acti-
vation of CD4+ T cells in a manner dependent on   MHCII 
molecules. If this event causes T cell activation, resulting in 
the production of critical cytokines, which might be IL-6 
family cytokines, at high enough levels to aff  ect the survival 
and growth of the target tissue or induce chronic infl  amma-
tion in the target tissue of a certain genetic background, the 
disease would be caused in a manner associated with MHCII 
as well as multiple genetic backgrounds that may aff  ect the 
target tissue, as reported for many autoimmune diseases, 
  including RA.
MATERIALS AND METHODS
Mice. F759 and FxxQ that have a human version of gp130 (S710L) were es-
tablished as described previously (27). C57BL/6 were obtained from SLC. 
129/B6-F759 or 129/B6-FxxQ heterozygous were crossed with C57BL/6 
over more than eight generations (N8). FxxQ homozygous mice were used 
at 14–15 d post-coitus as a result of the perinatal lethality. C57BL/6 back-
ground Igh6KO, CD4KO, CD8KO, and C2TAKO mice were purchased 
from The Jackson Laboratory and C57BL/6 background IL-6KO was pro-
vided by Dr. Iwakura (University of Tokyo, Tokyo, Japan). IL-7RKO was 
provided by Dr. Ikuta (Kyoto University, Kyoto, Japan). These mice were 
crossed with C57BL/6 F759 (N8) to obtain double mutant mice: Igh6KO/
F759, CD4KO/F759, CD8KO/F759, C2TAKO/F759, IL-6KO/F759, 
and IL-7RKO/F759. C57BL/6/SJL was also purchased from The Jackson 
  Laboratory. STAT3fl  ox/fl  ox mice were provided by Dr. Akira (Osaka Univer-
sity, Osaka, Japan). Alfa I collagen-Cre mice were provided by Dr. Karsenty 
(Baylor College of Medicine, Houston, TX). All mice were maintained under 
SPF conditions according to the instructions of the Osaka University Medical 
School. All animal experiments were performed following the guidelines of 
the Institutional Animal Care and Use Committees in Graduate School of 
Frontier Bioscience and Graduate School of Medicine, Osaka University.
Neonatal thymectomy. Neonatal thymectomy was performed as de-
scribed previously (30). In brief, C57BL/6 day 3 or day 7 neonates were 
anesthetized on ice and surgically thymectomized. Both lobes of the thymus 
were completely ablated with sterile toothpicks. The sternum and skin were 
sewed with 7–0 surgical sutures (Akiyama-Seisausho). Some neonates, whose 
skin and sternum were cut and sewn, were used as sham-operated mice.
Assessment of arthritis. Mice were inspected every week for up to 16 mo 
and assessed for signs of arthritis basically as described previously (28, 29). 
We modifi  ed the method minorly. Although we had removed scores of dead 
mice from the assessment, which usually had high scores (28, 29), here, we 
put the same scores from the point of time at which they were moribund or 
dead until end point of the assessment of the groups. The arthritis score 
shown is the sum of the scores for four limbs graded from 0 to 4. Thus, the 
maximum arthritis score for all four limbs was 16.
Histological analysis. Joints were fi  xed in 4% paraformaldehyde, decalci-
fi  ed for 12 h in Morse’s solution (22.5% bornyl formate and 10% sodium 
acid citrate solution) followed by 12 h in 4% paraformaldehyde, and embed-
ded in paraffi   n; sections were stained with hematoxylin/eosin (28).
BM transplantation. F759 and wild-type mice were irradiated (9.5 Gray) 
24 h before bone marrow injection. BM cells (2 × 106) were prepared from 
congenic-SJL or -F759 and intravenously injected into the irradiated host 
mice. 8 mo after the injection, >95% of the bone marrow cells were re-
placed with the donor (CD45.1) cells (unpublished data).
Antibodies and reagents. Antibodies against FITC-conjugated anti–mouse 
CD19, NK1.1, I-Aβ, PE-conjugated anti–mouse CD4, Cychrome-conjugated 
anti–mouse CD4, Gr-1, and CD11b, and allophycocyanin-conjugated anti–
mouse CD45.1 were purchased form eBioscience. Purifi  ed anti–mouse CD3ε, 
CD28, FITC-conjugated anti–mouse CD44, CD45.2 and PE-conjugated 
anti–mouse CD25 were obtained from Caltag. PE-conjugated anti–mouse 
CD62L was obtained from BD Biosciences. FITC-conjugated anti–mouse 
GITR was obtained from R&D Systems. Anti–IL-7 antibody (mouse IgG2b) 
was purifi  ed from M25 hybridoma culture supernatant. The M25 hybridoma 
was a gift from Dr. Marrack (National Jewish Medical and Research Center, 
Denver, CO). Control mouse IgG2b was purchased from Sigma-Aldrich.
Cell preparation and cell sorting. The LNs (inguinal, axillaries, cervical, 
and mesenteric) and spleen were harvested, passed through a 100-μm cell 
strainer (BD Falcon) with RPMI 1640, and washed. Erythrocytes were 
eliminated with 0.165 M NH4Cl. A T cell–enriched sample was prepared 
using a nylon wool column, and the CD4+CD44low or CD4+CD25− T cells JEM VOL. 203, June 12, 2006  1469
ARTICLE
were purifi  ed by a Mofl  o high-performance cell sorter (DakoCytomation). 
The purity of the CD4+ T cells was consistently >98%.
Flow cytometry. For cell surface staining, 106 T cells were incubated 
with fl  uorescence-conjugated antibodies for 30 min on ice. The cells were 
analyzed by fl   ow cytometry (BD Biosciences) using CELLQuest and 
Flowjo software.
In vivo IL-6 and anti–IL-7 antibody treatments. 1 μg of human IL-6 
(Toray) was intravenously injected into irradiated IL-6KO adult mice or 
nonirradiated IL-6KO/F759 (2 wk old). Anti–IL-7 antibody (0.1 mg) or 
mouse IgG2b antibody (0.1 mg) was intraperitoneally injected into 7-d-old 
neonatal thymectomized F759 every 2 d for 2 wk.
Homeostatic proliferation assay. CD44lowCD4+ T cells (106) were la-
beled with CFSE (Invitrogen) and i.p. injected into thymectomized neo-
nates or sublethally irradiated (5.0 Gray) adult mice. In some experiments, 
fi  ller CD25−CD4+ T cells were injected i.p. to inhibit HP in vivo. The re-
cipient neonates were killed at day 14 and recipient adults were killed on day 
9 for analysis of the cell division.
In vitro T cell proliferation assay. Sorted CD4+CD25− T cells (5 × 104) 
were cultured with 30 Gray irradiated splenocytes (5 × 104) in the presence 
of the indicated numbers of CD4+CD25+ T cells and anti-CD3e plus anti-
CD28 mAbs (0.5 μg/ml each) in 96-well U-bottom plates for 72 h at 37 
degree/5% CO2. All cell populations were sorted from wild-type C57BL6 
or F759 by Mofl  o. Cell proliferation was analyzed by TetraColor ONE 
(Seikagaku Corp.).
Fibroblast culture and stimulation. For splenic fi  broblast,  neonatal 
spleens (3 d after birth) of wild type and F759 were harvested and single cells 
were cultured in RPMI 1640 carrying 20% FCS. The medium was changed 
every week for 3 wk, as described previously (48). For MEFs, wild-type and 
FxxQ fetus (14–15 d post-coitus) were cultured in RPMI 1640 containing 
10% FCS and 1 mg/ml collagenase (Roche) in 5% CO2 incubator for 15 min. 
After washing the fetus twice with plain RPMI 1640, the suspensions of cells 
were prepared by cell strainer (BD Biosciences) and cultured in RPMI 1640 
containing 10% FCS for 5 d. The resulting MEFs (5 × 105/well) were plated 
in six-well plates and stimulated with IL-6 plus sIL-6R (50 ng/ml each) for 
6 h after 24 h of starvation in RPMI 1640 plus 0.1% FCS. Human IL-6 (Toray), 
human soluble IL-6 receptor (R&D Systems), mouse oncostatin M (R&D 
Systems), mouse CT-1 (R&D Systems), mouse IL-11 (R&D Systems), and 
mouse LIF (Chemicon) were used for the experiments (50 ng/ml each).
In vitro whole lymoph node culture and stimulation. The sLNs isolated 
from 5 Gray irradiated adult Col1a-STAT3 or controls were cut into <1-mm 
pieces and incubated in RPMI 1640 carrying 0.1% FCS in 5% CO2 incubator 
for 3 h with or without treatment of IL-6 plus sIL-6R (50 ng/ml each).
Real-time PCR. Gene Amp 5700, SYBER green PCR Master Mix 
(ABI Warrington) was used for IL-6 mRNA and SOCS3 quantifi  cation. 
Taqman Universal PCR Master Mix (Applied Biosystems) was used for 
IL-7 mRNA and Foxp3 mRNA quantifi  cation. The mRNAs were pre-
pared from purifi  ed CD4+ T cells or a mixture of sLNs using Sepasol-RNA 
I (Nakalai), RNA-mini preparation kit (QIAGEN), RNase free DNase kit 
(QIAGEN), and used for the synthesis of cDNAs. The combinations of PCR 
primers and Taqman probes for real-time PCR were as follows: HPRT 
primers; 5′-G  A  T  T  A  G  C  G  A  T  G  A  T  G  A  A  C  C  A  G  G  T  T  -3′ and 5′-C  C  T  C  C  C-
A  T  C  T  C  C  T  T  C  A  T  G  A  C  A  -3′; IL-6 primers, 5′-G  A  G  G  A  T  A  C  C  A  C  T  C  C-
C  A  A  C  A  G  A  C  C  -3′ and 5′-A  A  G  T  G  C  A  T  C  A  T  C  G  T  T  G  T  T  C  A  T  A  C  A  -3′; 
SOCS3 primers, 5′-G  C  G  A  G  A  A  G  A  T  T  C  C  G  C  T  G  G  T  A  -3′ and 5′-C  G  T-
T  G  A  C  A  G  T  C  T  T  C  C  G  A  C  A  A  A  G  -3′; β-actin primers, 5′-A  G  A  G  G  G  A  A-
A  T  C  G  T  G  C  G  T  G  A  C  -3′ and 5′-C  A  A  T  A  G  T  G  A  T  G  A  C  C  T  G  G  C  C  G  T  -3′; 
β-actin Taqman probe, FAM-C  A  C  T  G  C  C  G  C  A  T  C  C  T  C  T  T  C  C  T  C  C  C  -
TAMRA-3′; IL-7 primers, 5′-C  T  G  C  A  G  T  C  C  C  A  G  T  C  A  T  C  A  T  G  A  -3′ 
and 5′-G  T  G  G  C  A  C  T  C  A  G  A  T  G  A  T  G  T  G  A  C  A  -3′; IL-7 Taqman probe, 
FAM-C  C  T  C  C  C  G  C  A  G  A  C  C  A  T  G  T  T  C  C  A  T  G  T  -TAMRA-3′; and Foxp3 
primers; 5′-G  G  C  C  C  T  T  C  T  C  C  A  G  G  A  C  A  G  A  -3′ and 5′-G  C  T  G  A  T  C  A  T  G-
G  C  T  G  G   GTTGT-3′; Foxp3 Taqman probe; FAM-A  C  T  T  C  A  T  G  C  A  T  C  A-
G  C  T  C  T  C  C  A  C  T  G  T  G  G  A  T  -TAMRA. The conditions for real-time PCR 
were 94°C for 5 s and 60°C for 60 s for 40 cycles. The relative IL-6 and 
SOCS3 or IL-7 and foxp3 mRNA expressions were calculated as ratios to 
the HPRT or β-actin mRNA copy numbers.
We calculated the relative gene expression as follows; dividing the abso-
lute copy number of target genes by the absolute copy number of house-
keeping genes, such as HPRT or β-actin. We showed the raw data without 
normalizing them in fi  gures of real-time PCR experiments.
Western blotting of IL-7 protein. The sLNs of irradiated type I-  collagen-
Cre/STAT3fl  ox/fl  ox, wild type, or F759 were lysed with NP-40 cell lysis buf-
fer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl and 1% NP-40) containing 
protease inhibitors (Sigma-Aldrich). Protein fraction was purifi  ed by 2D 
Cleanup kit (BioRad Laboratories). After SDS page on a 10–20% gel, the 
protein fraction was applied on Western blotting analysis with anti–mouse 
IL-7 antibody (R&D Systems) plus horseradish peroxidase secondary anti-
body (Zymed Laboratories) and visualized by ECL (GE Healthcare).
Statistical analysis. All the data were statistically analyzed with a Student’s 
t test.
Online supplemental material. Data regarding CD25+CD4+ T cells in 
F759 and N7Txed F759 mice is shown in Fig. S1, A–E, which is available at 
http://www.jem.org/cgi/content/full/jem.20052187/DC1.
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